Thank you everyone for your input. I was slightly expecting "you should have done this and you should have done that!" I have spread my portfolio over a range of industries. Some are doing really well, some are doing average. ACR speaks for itself. I remember looking at ACR Product Bar Charts with all these potential products expected to come on line in the not too distant future back in Feb/Mar 2014. Two years later, I do not look at them. I am unsure if I should believe it????
"However as you cannot claim a CGT loss on these shares."
Wow, this is something I did not realise. Luckily I did not sell. I am holding on as a lesson for me.
Sorry if I have't really added any real discussion about ACR itself. I only wanted to have a rant where I can just tell everyone where I am going wrong. I still have so much to learn. I thought that the new CEO in Nov 2014 would change things a bit??????
Products:
Antifugal (Onychomycosis), Pain and Inflammation (Diclofenac), Pain and Inflammation (Ibuprofen) at Pre-Clinic Development
Initial generic portfolio and Companion animal health (with Elanco): maybe they have an confidential agreement with someone??????? Only guessing?
Thank you everyone for your input over the past two years that I have been reading. Only wished I knew a little bit so that I could add to your discussions.
ACR Price at posting:
66.5¢ Sentiment: Hold Disclosure: Held
